Medtronic

Extracorporeal Membrane Oxygenation Machine Market Projected to Reach $1,085.63 million by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Wednesday, March 13, 2024
Temperature, Component, Growth, LivaNova, Extracorporeal membrane oxygenation, Getinge Group, Intelligence, Fresenius Medical Care, Incidence, COVID-19, Patient, Pulmonary hypertension, Research, Cannula, Meconium aspiration syndrome, Carbon, ECMO, Heart, Arteriovenous, Periodic breathing, Workforce, Blood, Hemolysis, Medtronic, Nursing care plan, PPHN, Table, Ageing, Medical device

The extracorporeal membrane oxygenation (ECMO) machine, a crucial medical device, offers extended cardiac and respiratory support to patients with insufficient gas exchange capabilities, marking a significant advancement in critical care.

Key Points: 
  • The extracorporeal membrane oxygenation (ECMO) machine, a crucial medical device, offers extended cardiac and respiratory support to patients with insufficient gas exchange capabilities, marking a significant advancement in critical care.
  • Furthermore, market prospects include integrating ECMO with other extracorporeal treatments and concentrated research efforts to expand usage indications.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Extracorporeal Membrane Oxygenation Machine Market.
  • "Dive into the Extracorporeal Membrane Oxygenation Machine Market Landscape: Explore 196 Pages of Insights, 474 Tables, and 26 Figures"

Medical technology back on track

Retrieved on: 
Wednesday, March 13, 2024
Hospital, CNMV, Growth, Annual report, TEL, Cigna, House, Health, Acceleration, Intuitive Surgical, Medtech, Post office box, SICAV, Judgement, Humana, HCA Healthcare, Congress, Environment, Lux, South, Harmony Row, Conference, AG, Medtronic, Capital, Investment, Research, Prospectus, Intelligence, SIX Swiss Exchange, CHF, Intuition, Risk, Medicare, Grand Canal Dock, Pharmaceutical industry

The broad healthcare sector and the medical technology sector, buoyed by resurgent investor interest, delivered even better returns.

Key Points: 
  • The broad healthcare sector and the medical technology sector, buoyed by resurgent investor interest, delivered even better returns.
  • “We also anticipate a big boost in growth from the increasing use of artificial intelligence in the medical technology and healthcare services industries,” Stefan Blum adds.
  • These were generally characterized by strong growth momentum in surgical procedures and an optimistic outlook for the 2024 fiscal year,” Marcel Fritsch comments.
  • Elevance, which is focused on employer-sponsored health insurance plans, reported better-than-expected profits thanks to a drop in medical costs and an increase in management’s earnings guidance for 2024.

Perceptyx Announces INSIGHTS 2024 World Tour

Retrieved on: 
Wednesday, February 28, 2024
SVP, City, HR, Education minister, Medtronic, Comcast, Management

TEMECULA, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Perceptyx , the global leader in employee experience (EX) transformation, is taking its annual INSIGHTS conference on a global tour.

Key Points: 
  • TEMECULA, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Perceptyx , the global leader in employee experience (EX) transformation, is taking its annual INSIGHTS conference on a global tour.
  • INSIGHTS 2024 will reveal how global enterprises are using employee insights to drive business outcomes in a series of one-day events across five cities and two continents:
    INSIGHTS 2024 is an opportunity for people leaders across industries to connect, share successes, and exchange ideas on designing employee listening strategies for maximum impact.
  • “INSIGHTS 2024 provides CHROs and HR leaders a space to network and discuss the latest approaches to creating better employee experiences.
  • We’re thrilled to gather industry experts in one place to share insights and learn how technology can help them achieve positive business outcomes.”
    Qualified senior HR leaders can register here to attend any of the free INSIGHTS tour events.

Endologix Appoints Mike Mathias as Chief Commercial Officer

Retrieved on: 
Tuesday, March 5, 2024
Biotechnology, General Health, Medical Devices, Health, Pharmaceutical, TAVR, MD, Strategic planning, MBA, Percutaneous aortic valve replacement, University, Vascular disease, Peripheral artery disease, Organization, Medtronic, EVAR, Endovascular aneurysm repair

Endologix LLC , a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, announced the appointment of Mike Mathias as the company’s Chief Commercial Officer, effective immediately.

Key Points: 
  • Endologix LLC , a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, announced the appointment of Mike Mathias as the company’s Chief Commercial Officer, effective immediately.
  • With a distinguished 30-year career in leading commercial organizations within the cardiovascular arena, Mike brings a wealth of experience and a proven track record of success to Endologix.
  • Mike is uniquely qualified to lead our global commercial team and continue the strategic development of our commercial plans.
  • In response to his new role, Mike Mathias shared, "Joining Endologix at such a critical juncture is an honor.

Axonics Responds to ITC Action by Medtronic

Retrieved on: 
Thursday, February 29, 2024
Radiology, Health Technology, Health, Medical Devices, Medtronic, Patient, ITC, Incontinence, District court, MRI, Synovial joint

Axonics, Inc. (Nasdaq: AXNX) today announced that it has received notice that Medtronic has filed a complaint with the U.S. International Trade Commission (ITC), along with a parallel action in U.S. District Court for the District of Delaware.

Key Points: 
  • Axonics, Inc. (Nasdaq: AXNX) today announced that it has received notice that Medtronic has filed a complaint with the U.S. International Trade Commission (ITC), along with a parallel action in U.S. District Court for the District of Delaware.
  • The complaint alleges that Axonics infringes two Medtronic patents that purportedly relate to a “patient programmer with automated MRI compatibility verification” for an implantable medical device.
  • Axonics took a different path and created a renaissance in sacral neuromodulation therapy by developing long-lived implantable devices and introducing full-body MRI compatibility in this category for the first time.
  • Axonics refuses to be intimidated by Medtronic and intends to defend itself vigorously.

Spinal Non-Fusion Devices Market Poised for Growth: Global Insights and Forecast to 2030 - Escalating Prevalence of Spinal Disorders, Advanced Product Options, and Product Developments - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 27, 2024
Biotechnology, General Health, Surgery, Medical Devices, Health, Spine, Incidence, Competitive landscape, USD, FDA, Ageing, Growth, World Health Organization, Projection, Prevalence, Tetraplegia, Medtronic, NuVasive, Accident, Research, Medical device

The "Spinal Non-Fusion Devices Market Insights, Competitive Landscape and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Spinal Non-Fusion Devices Market Insights, Competitive Landscape and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • According to a detailed market assessment, the Spinal Non-Fusion Devices sector was valued at a commendable USD 2,757.17 million in the year 2023.
  • The expected growth trajectory is attributed to the escalating prevalence of spinal disorders, advanced product options, and burgeoning product development endeavors.
  • With specialized segmentation ranging from product type to global geography, this comprehensive market assessment elucidates the dynamic environment of the Spinal Non-Fusion Devices market.

Reprieve Cardiovascular Emerges from Stealth Mode after $42 Million Series A Financing to Bring Intelligent Fluid Management to Heart Failure Patients

Retrieved on: 
Tuesday, February 20, 2024
Health, Medical Devices, Health Technology, General Health, Clinical Trials, Cardiology, Biotechnology, Volume overload, Pacyna, Diuretic, Physician, Acute decompensated heart failure, Leg, Standard of care, Heart failure, ADHF, FASTR, Reprieve, Fatigue, Patient, Medtronic, Circulatory system, Pharmaceutical industry

Reprieve Cardiovascular , Inc., a development stage company focused on pioneering an intelligent automated diuretic and fluid management approach for acute decompensated heart failure (ADHF) treatment, today announced it has raised a total of $42 million in series A financing.

Key Points: 
  • Reprieve Cardiovascular , Inc., a development stage company focused on pioneering an intelligent automated diuretic and fluid management approach for acute decompensated heart failure (ADHF) treatment, today announced it has raised a total of $42 million in series A financing.
  • The total round was co-led by Lightstone Ventures and Sante Ventures and joined by Deerfield Management, Genesis Capital, and Arboretum Ventures.
  • The funding will advance the Company’s clinical and development programs, including the ongoing FASTR trial and its upcoming pivotal trial.
  • Pacyna continued, “Reprieve Cardiovascular is bringing intelligent decongestion management to heart failure patients.

New real-world data shows MiniMed™ 780G system sustains strong global performance, exceeding international targets for diabetes management

Retrieved on: 
Saturday, March 9, 2024
TIR, TITR, CGM, MD, Medtronic, AID, Cohort (statistics), Conference, ATTD, Health, Endocrinology, Therapy, DCCT

DUBLIN and FLORENCE, Italy, March 9, 2024 /PRNewswire/ -- Medtronic plc. (NYSE: MDT), a global leader in healthcare technology, today shared a robust set of new clinical and real-world evidence on the MiniMed™ 780G system from around the world including the largest set of data from early users in the United States. The data was presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Florence, Italy. These results build on the 3-year data published in Diabetes Technology & Therapeutics showing over 100,000 real-world users achieving a Time in Range (TIR) of 78% with the use of recommended optimal settings, outperforming international targets of 70% TIR.

Key Points: 
  • The data was presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Florence, Italy.
  • These results build on the 3-year data published in Diabetes Technology & Therapeutics showing over 100,000 real-world users achieving a Time in Range (TIR) of 78% with the use of recommended optimal settings, outperforming international targets of 70% TIR.
  • In an oral presentation, Dr. James Thrasher, MD, Founder, Arkansas Diabetes and Endocrinology Center, shared data on early real-world users with type 1 diabetes of the MiniMed™ 780G system in the U.S. (n=7,499).
  • This data reinforces that the determinant of choice for AID systems should be first and foremost the power of the algorithm."

SHE Media's Second Annual Co-Lab at SXSW® Elevating Leading Voices in Women's Health to the Mainstage

Retrieved on: 
Friday, March 8, 2024
Narrative, SXSW, The New York Times, Media, AI, Colorectal cancer, Health, IVF, American Medical Association, Commerce, Risk, Impossible, Ipsen, Entrepreneurship, Patient, Yoga, Cardiovascular disease, Medtronic, Heart, Host, Science, Journalist, Artificial intelligence, Consciousness, SHE Media

AUSTIN, Texas, March 8, 2024 /PRNewswire/ -- Today, SHE Media, a mission-driven media company, announced its full agenda and latest speaker lineup for the Co-Lab: Whole Life Health at South by Southwest® (SXSW®). The highly anticipated activation, in its second year, will take place March 9, 10 and 11 in Downtown Austin at 206 E 4th St. Attendees will hear from experts, advocates, and thought leaders as they share both the science and stories of women's whole life health including the latest innovations and how technology is revolutionizing healthcare. Doors will open daily at 9am and close at 5pm with panel discussions and fireside chats programmed throughout the day. Full agenda details and updates can be found here.

Key Points: 
  • Doors will open daily at 9am and close at 5pm with panel discussions and fireside chats programmed throughout the day.
  • The Co-Lab at SXSW marks the one-year anniversary of launching Flow Space , SHE Media's proprietary digital and live media platform providing content, community, and commerce in service of women's health.
  • Learn how we can better care for our hearts, including how symptoms differ in women, preventative measures and innovations that can reduce risk.
  • plusOne® Sexual Wellness in Full Bloom | Attendees can celebrate sexual wellness by stopping by the plusOne® flower cart to receive a tote and Rose Arouser.

Medtronic EVP & CFO Karen Parkhill to participate in the Barclays healthcare conference

Retrieved on: 
Tuesday, March 5, 2024
EDT, Medtronic, CDT, Q&A, Barclays

DUBLIN, March 5, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will participate in the 26th annual Barclays global healthcare conference on Tuesday, March 12, 2024.

Key Points: 
  • DUBLIN, March 5, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will participate in the 26th annual Barclays global healthcare conference on Tuesday, March 12, 2024.
  • Karen Parkhill, Medtronic executive vice president and chief financial officer, will answer questions on the company beginning at 8:00 a.m. EDT (7:00 a.m. CDT).
  • A live webcast of the Q&A session will be available on March 12, 2024, by clicking on the Events link at http://investorrelations.medtronic.com .
  • An archive of the Q&A session will be available on the same webpage later in the day.